TBCE and metabolic dysfunction-associated steatohepatitis: Interestingly, targeting CD163 in KCs and other M2 macrophages with an anti-CD163-IgG-dexamethasone conjugate has been shown to improve MASH pathologies, including hepatic inflammation, hepatocyte ballooning, fibrosis, and glycogen deposition in a rat model of fructose-induced MASH [167].